A review on vasohibin and ocular neovascularization
Author:
Corresponding Author:

Yu-Zhi Ding. Zhongda Hospital Southeast University, Nanjing 210000, Jiangsu Province, China. dr_dingyuzhi@163.com

Affiliation:

Clc Number:

Fund Project:

Supported by Natural Science Fund Project in Jiangsu Province (No.BK20180380); Nanjing Health Commission (No.YKK18260).

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Ischemic and neovascular disease is one of the most difficult ocular diseases to deal with nowadays. Redundancy, poor visual acuity and decreased life quality are bothering patients and ophthalmologists for decades. After vascular endothelial growth factor (VEGF) was found to be a primary factor in promoting retinal angiogenesis, intravitreal injection of anti-VEGF drugs has been the first-line treatment. Whereas, some patients are refractory to this therapy and problems of economic burden, local complications and adverse effects promote researches into other possible targets. The vasohibin (VASH) family is a newly-investigated factor in modulating ocular angiogenesis. The family includes VASH1 and VASH2, which show opposite effects of inhibiting and accelerating angiogenesis respectively. Positive results have been reported in cellular and animal experiments. With further researches, it can be a promising future target of treating ocular neovascular diseases.

    Reference
    Related
    Cited by
Get Citation

Hu XN, Ni Y, Luan J, Ding YZ. A review on vasohibin and ocular neovascularization. Int J Ophthalmol 2020;13(6):1004-1008

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:August 30,2019
  • Revised:October 16,2019
  • Adopted:
  • Online: April 28,2020
  • Published: